.Pharmacolibrary.Drugs.ATC.N.N02CD03

Information

Fremanezumab is a fully humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), used to prevent migraine attacks in adults. It is approved and currently used as a preventive therapy for migraine, reducing headache frequency and severity.

Pharmacokinetics

Population pharmacokinetic model reported for adult patients (including healthy subjects and migraine patients) aged 18–70 years. Parameters represent results after subcutaneous administration.

References

1. Fiedler-Kelly, JB, et al., & Levi, M (2019). Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. British journal of clinical pharmacology 85(12) 2721–2733. DOI:10.1111/bcp.14096 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31418911

2. Cohen-Barak, O, et al., & Rabinovich-Guilatt, L (2021). Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach. Cephalalgia : an international journal of headache 41(10) 1065–1074. DOI:10.1177/03331024211007789 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34000848

3. Cohen-Barak, O, et al., & Aycardi, E (2018). A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia : an international journal of headache 38(13) 1960–1971. DOI:10.1177/0333102418771376 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29667896

Revisions

• 06/2025 initial generated model